Cargando…
Distinguishing mutants that resist drugs via different mechanisms by examining fitness tradeoffs across hundreds of fluconazole-resistant yeast strains
There is growing interest in designing multidrug therapies that leverage tradeoffs to combat resistance. Tradeoffs are common in evolution and occur when, for example, resistance to one drug results in sensitivity to another. Major questions remain about the extent to which tradeoffs are reliable, s...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cold Spring Harbor Laboratory
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10614906/ https://www.ncbi.nlm.nih.gov/pubmed/37905147 http://dx.doi.org/10.1101/2023.10.17.562616 |
_version_ | 1785129118651645952 |
---|---|
author | Schmidlin Apodaca Newell Sastokas Kinsler Geiler-Samerotte |
author_facet | Schmidlin Apodaca Newell Sastokas Kinsler Geiler-Samerotte |
author_sort | Schmidlin |
collection | PubMed |
description | There is growing interest in designing multidrug therapies that leverage tradeoffs to combat resistance. Tradeoffs are common in evolution and occur when, for example, resistance to one drug results in sensitivity to another. Major questions remain about the extent to which tradeoffs are reliable, specifically, whether the mutants that provide resistance to a given drug all suffer similar tradeoffs. This question is difficult because the drug-resistant mutants observed in the clinic, and even those evolved in controlled laboratory settings, are often biased towards those that provide large fitness benefits. Thus, the mutations (and mechanisms) that provide drug resistance may be more diverse than current data suggests. Here, we perform evolution experiments utilizing lineage-tracking to capture a fuller spectrum of mutations that give yeast cells a fitness advantage in fluconazole, a common antifungal drug. We then quantify fitness tradeoffs for each of 774 evolved mutants across 12 environments, finding these mutants group into 6 classes with characteristically different tradeoffs. Their unique tradeoffs may imply that each group of mutants affects fitness through different underlying mechanisms. Some of the groupings we find are surprising. For example, we find some mutants that resist single drugs do not resist their combination, and some mutants to the same gene have different tradeoffs than others. These findings, on one hand, demonstrate the difficulty in relying on consistent or intuitive tradeoffs when designing multidrug treatments. On the other hand, by demonstrating that hundreds of adaptive mutations can be reduced to a few groups with characteristic tradeoffs, our findings empower multidrug strategies that leverage tradeoffs to combat resistance. Finally, by grouping mutants that likely affect fitness through similar underlying mechanisms, our work guides efforts to map the phenotypic effects of mutation. |
format | Online Article Text |
id | pubmed-10614906 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Cold Spring Harbor Laboratory |
record_format | MEDLINE/PubMed |
spelling | pubmed-106149062023-10-31 Distinguishing mutants that resist drugs via different mechanisms by examining fitness tradeoffs across hundreds of fluconazole-resistant yeast strains Schmidlin Apodaca Newell Sastokas Kinsler Geiler-Samerotte bioRxiv Article There is growing interest in designing multidrug therapies that leverage tradeoffs to combat resistance. Tradeoffs are common in evolution and occur when, for example, resistance to one drug results in sensitivity to another. Major questions remain about the extent to which tradeoffs are reliable, specifically, whether the mutants that provide resistance to a given drug all suffer similar tradeoffs. This question is difficult because the drug-resistant mutants observed in the clinic, and even those evolved in controlled laboratory settings, are often biased towards those that provide large fitness benefits. Thus, the mutations (and mechanisms) that provide drug resistance may be more diverse than current data suggests. Here, we perform evolution experiments utilizing lineage-tracking to capture a fuller spectrum of mutations that give yeast cells a fitness advantage in fluconazole, a common antifungal drug. We then quantify fitness tradeoffs for each of 774 evolved mutants across 12 environments, finding these mutants group into 6 classes with characteristically different tradeoffs. Their unique tradeoffs may imply that each group of mutants affects fitness through different underlying mechanisms. Some of the groupings we find are surprising. For example, we find some mutants that resist single drugs do not resist their combination, and some mutants to the same gene have different tradeoffs than others. These findings, on one hand, demonstrate the difficulty in relying on consistent or intuitive tradeoffs when designing multidrug treatments. On the other hand, by demonstrating that hundreds of adaptive mutations can be reduced to a few groups with characteristic tradeoffs, our findings empower multidrug strategies that leverage tradeoffs to combat resistance. Finally, by grouping mutants that likely affect fitness through similar underlying mechanisms, our work guides efforts to map the phenotypic effects of mutation. Cold Spring Harbor Laboratory 2023-11-01 /pmc/articles/PMC10614906/ /pubmed/37905147 http://dx.doi.org/10.1101/2023.10.17.562616 Text en https://creativecommons.org/licenses/by-nc-nd/4.0/This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which allows reusers to copy and distribute the material in any medium or format in unadapted form only, for noncommercial purposes only, and only so long as attribution is given to the creator. |
spellingShingle | Article Schmidlin Apodaca Newell Sastokas Kinsler Geiler-Samerotte Distinguishing mutants that resist drugs via different mechanisms by examining fitness tradeoffs across hundreds of fluconazole-resistant yeast strains |
title | Distinguishing mutants that resist drugs via different mechanisms by examining fitness tradeoffs across hundreds of fluconazole-resistant yeast strains |
title_full | Distinguishing mutants that resist drugs via different mechanisms by examining fitness tradeoffs across hundreds of fluconazole-resistant yeast strains |
title_fullStr | Distinguishing mutants that resist drugs via different mechanisms by examining fitness tradeoffs across hundreds of fluconazole-resistant yeast strains |
title_full_unstemmed | Distinguishing mutants that resist drugs via different mechanisms by examining fitness tradeoffs across hundreds of fluconazole-resistant yeast strains |
title_short | Distinguishing mutants that resist drugs via different mechanisms by examining fitness tradeoffs across hundreds of fluconazole-resistant yeast strains |
title_sort | distinguishing mutants that resist drugs via different mechanisms by examining fitness tradeoffs across hundreds of fluconazole-resistant yeast strains |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10614906/ https://www.ncbi.nlm.nih.gov/pubmed/37905147 http://dx.doi.org/10.1101/2023.10.17.562616 |
work_keys_str_mv | AT schmidlin distinguishingmutantsthatresistdrugsviadifferentmechanismsbyexaminingfitnesstradeoffsacrosshundredsoffluconazoleresistantyeaststrains AT apodaca distinguishingmutantsthatresistdrugsviadifferentmechanismsbyexaminingfitnesstradeoffsacrosshundredsoffluconazoleresistantyeaststrains AT newell distinguishingmutantsthatresistdrugsviadifferentmechanismsbyexaminingfitnesstradeoffsacrosshundredsoffluconazoleresistantyeaststrains AT sastokas distinguishingmutantsthatresistdrugsviadifferentmechanismsbyexaminingfitnesstradeoffsacrosshundredsoffluconazoleresistantyeaststrains AT kinsler distinguishingmutantsthatresistdrugsviadifferentmechanismsbyexaminingfitnesstradeoffsacrosshundredsoffluconazoleresistantyeaststrains AT geilersamerotte distinguishingmutantsthatresistdrugsviadifferentmechanismsbyexaminingfitnesstradeoffsacrosshundredsoffluconazoleresistantyeaststrains |